Eupraxia Pharmaceuticals Announces Key Leadership Changes To Support Expansion

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company developing locally delivered therapies using its proprietary Diffusphere™ drug delivery platform, has announced several executive leadership and organizational changes as it prepares for the next stage of its clinical and commercial growth. The updates are designed to strengthen the company's capabilities in research, development, manufacturing, and commercialization as its lead programs advance toward late-stage development.

As part of the leadership expansion, Dr. Jeff Millard has joined Eupraxia as Executive Vice President, Technical Operations, effective July 13, 2026. In his new role, he will oversee the company's technical operations, chemistry, manufacturing and controls (CMC), and regulatory strategy. Dr. Millard brings nearly 25 years of experience across the biotechnology industry, having held senior leadership positions at Ensysce Biosciences, Microbion Corporation, and Cascadian Therapeutics. Throughout his career, he has guided multiple product candidates from early research through regulatory approval and commercialization. Eupraxia believes his expertise in scaling operations and preparing therapies for commercial launch will play a key role in supporting the future development of its lead candidate, EP104GI.

The company has also expanded the responsibilities of Dr. Alex Therien, who joined Eupraxia in November 2025. He has been appointed Executive Vice President, Research & Development and will now lead the company's entire research and development organization. Dr. Therien has more than two decades of experience in the biopharmaceutical sector, having previously held senior leadership positions at Generate Biomedicines, Eikon Therapeutics, and Merck. Eupraxia expects his scientific and strategic expertise to help accelerate the growth of its development pipeline and support future portfolio expansion.

Chief Executive Officer Dr. James Helliwell said the company is entering a critical period of growth as it prepares for the interim data release from the Phase 2b RESOLVE trial in eosinophilic esophagitis (EoE), expected in the fourth quarter of 2026. He described the upcoming data as an important milestone for both the company and the expansion of its gastrointestinal disease portfolio.

Dr. Helliwell explained that the encouraging results generated in the earlier Phase 2a RESOLVE study have increased the company's focus on preparing for potential Phase 3 development, regulatory submissions, manufacturing scale-up, and future commercialization activities. He added that the appointment of experienced executives, together with the recent addition of highly qualified board members, reflects Eupraxia's transition from an early-stage biotechnology company into a late-stage clinical organization with the leadership needed to support its next phase of growth.

Alongside the executive appointments, Eupraxia has completed an operational restructuring to support its expanding clinical and commercial activities. The company has transitioned its operations from Victoria, British Columbia, to a two-hub model based in Vancouver, Canada, and Seattle, Washington. Under this new structure, key executive leadership positions responsible for clinical development, manufacturing, commercialization, and overall corporate strategy, including the Chief Executive Officer, will be based in the Seattle office. The company believes this organizational shift will better position it to manage its growing pipeline and future commercial operations across North America.

As part of the transition, Amanda Malone has stepped down from her role as Chief Scientific and Operating Officer, effective July 10, 2026. Based in Victoria, Malone played an important role in advancing Eupraxia's scientific research and early-stage development programs. The company expressed its appreciation for her years of leadership and contributions, acknowledging her efforts in helping establish the scientific foundation that has supported the advancement of its pipeline.

With these leadership appointments and organizational changes, Eupraxia is strengthening its executive team and operational infrastructure as it advances toward late-stage clinical development. The company expects these initiatives to support the continued development of EP104GI, expand its gastrointestinal portfolio, and position the business for future regulatory approvals and commercialization opportunities.